Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions
Completed · Not applicable
Conditions studied: Insomnia
In brief
The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Key facts
- Study ID
- NCT00601666
- Run by
- Roxane Laboratories
- People needed
- 30
- Starts
- 2004-03-01
- Expected to finish
- 2004-03-01
- Last updated by the study team
- 2018-01-23
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
You may not qualify if…
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Zolpidem or any comparable or similar product.
Where it is running
- PRACS Institute, Ltd. — Fargo, North Dakota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.